Introduction
============

Alzheimer's disease (AD) is the most common form of dementia and represents a complex and multi-factorial disorder. Hallmarks of the disease are the accumulation of abnormal beta-amyloid (Aβ) and neurofibrillary tangles composed of hyperphosphorylated microtubule-associated tau protein, leading to neurodegeneration ([@B8]). Misfolded Aβ and tau protein bind to receptors on microglia and astroglia, and trigger innate immune responses, which contribute to disease progression and severity ([@B15]). In addition, alterations in the density and morphology of cerebral vasculature, a regional reduction of cerebral blood flow (CBF) and an impaired cerebral vascular reactivity (CVR) have been reported in patients with AD and mild cognitive impairment ([@B11]; [@B21]), and have been implicated to contribute to the cognitive impairment.

Several neuroimaging techniques have been developed to assess features of AD pathology in patients and animal models of the disease. The quest is to improve the diagnosis of the disease, to assess the disease stage, to select patients for treatment and to monitor the response to therapy. Among them, magnetic resonance imaging (MRI) has been used to detect degenerative changes in patients with AD ([@B14]). More recently, functional MRI (fMRI) techniques have been implemented to evaluate cerebrovascular abnormality in patients with AD, which has been shown to occur early during the disease course ([@B16]). These comprise regional changes in CBF ([@B32]) and microvessel density ([@B22]), disturbances of blood--brain barrier integrity ([@B35]), impairment of vascular reactivity ([@B49]; [@B36]; [@B45]; [@B12]), and vascular remodeling ([@B12]; [@B23]).

The kallikrein-kinin system has been implicated as an important pathophysiological mediator of cerebral vascular dysfunction, neuroinflammation and Aβ pathology in AD ([@B47]; [@B41]). Kinins, in particular bradykinin, are pro-inflammatory mediators with a range of physiological effects in the periphery, which have also been described in the central nervous system ([@B10]). Bradykinin, lysine-bradykinin, and bradykinin degradation products act through the activation of two G protein-coupled bradykinin receptors (BRs): B~1~R and B~2~R. Pharmacological antagonism or genetic deletion of B~1~R ([@B44]; [@B27]; [@B42]; [@B4]) and B~2~R ([@B6]; [@B9]) have been shown to alleviate the cognitive deficits in Aβ-injected or transgenic AD animal models.

In the present study, we hypothesized that chronic oral treatment with the phthalideisoquinoline alkaloid noscapine, a B~1~R and B~2~R antagonist ([@B28]), ameliorates the CBF and CVR abnormalities in arcAβ mouse model of amyloidosis ([@B34]). We investigated the effect of BR blockade by noscapine on CBF and CVR in arcAβ mice using fMRI techniques. In addition, we studied the effects of noscapine treatment on Aβ deposits and microglia by immunohistochemical and biochemical analysis.

Materials and Methods {#s1}
=====================

Animals
-------

All experiments were performed in accordance with the Swiss Federal Act on Animal Protection and were approved by the Cantonal Veterinary Office Zurich (Permit Number: 90-2016). All procedures fulfilled the ARRIVE guidelines on reporting animal experiments. ArcAβ transgenic mice, with human APP695 transgene containing the Swedish (K670N/M671L) and Arctic (E693G) mutation under the control of the prion protein promoter ([@B25]), were used. Animals were kept in a temperature-controlled room in individually ventilated cages under 12 h light/dark cycle and access to pelleted food and water were provided *ad libitum*. Paper tissue was given as environmental enrichment. A sample size of *n* = 7 per group was calculated for the primary end point CBF, a fixed effect omnibus, one-way ANOVA with four groups, and an effect size *f* = 0.72, α = 0.05 and β = 0.2. Consequently, group sizes *n* \> 7 were used (G^∗^power, University of Düsseldorf, Germany).

Measurement of Plasma Bradykinin Levels
---------------------------------------

Six arcAβ and seven non-transgenic littermates (NTLs) of 17 months-of-age were used. Blood from the vena cava of the mice was collected into Eppendorf tubes filled with 50 μl 0.5 M ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich GmbH, Switzerland) and centrifuged at 4°C, 1000 *g* for 15 min. The blood : EDTA volume ratio was approximately 8:1. The plasma supernatants were collected as 50 μl aliquots, frozen and kept at -80°C, until use. The enzyme immunoassay (RayBiotech, Norcross, GA, United States) was used for bradykinin level measurement. A known concentration of biotinylated bradykinin was spiked into samples and standards, which were then added to wells. Here, biotinylated-bradykinin competes with the endogenous bradykinin in plasma for binding to the monoclonal anti-bradykinin antibody immobilized on the wall. After color development reaction, the intensity of the colorimetric signal was directly proportional to the amount of biotinylated bradykinin captured by the antibody, which inversely correlated to the amount of endogenous peptide in the sample or standard. A standard curve for the quantification of bradykinin concentration in the samples was generated. The lower detection limit of the assay was 1.4 ng/ml bradykinin.

Study Design Noscapine Treatment
--------------------------------

A flowchart of the design for the noscapine treatment study is shown in [Supplementary Figure 1](#SM1){ref-type="supplementary-material"}. Twenty arcAβ and 17 NTLs of both genders at approximately 14 months-of-age (at the start of the study) were used for the 3 months treatment study ([Table 1](#T1){ref-type="table"}). Animals of both genders were randomly allocated to experimental groups. Experimenters were blinded during data acquisition and analysis. Mice in the treatment arm were supplied with noscapine (Sigma-Aldrich GmbH, Switzerland) in acidified drinking water for 3 months before the first measurement. Noscapine (3 g/l) was dissolved in double distilled water, adjusted to pH 3.5 (Sigma-Aldrich GmbH, Switzerland). Prior to the treatment study, high performance liquid chromatography was performed to measure the stability of noscapine in acidified double distilled water (pH 3.5), where 94 and 70% of noscapine were detectable after 24 h and 2 days, respectively. Therefore, we prepared fresh noscapine solution (pH 3.5) daily and protected it from light to ensure stability. For the control group, double distilled water was provided. All animals were weighed once per week during the study. Blood pressure of the mice were assessed non-invasively at the end of the treatment by tail-cuff using CODA monitor (Kent Scientific, Corp., Torrington, CT, United States). Systolic and diastolic blood pressures of each mice were assessed consecutively twenty times, and were averaged ([Table 1](#T1){ref-type="table"}).

###### 

Demographic information, weight, and blood pressure of mice.

  Group                            NTL           NTL noscapine   arcAβ          arcAβ noscapine
  -------------------------------- ------------- --------------- -------------- -----------------
  *N*                              8             9               9              11
  Female/male                      4/4           7/2             5/4            4/7
  Age (months)^∗^                  16.6 ± 0.3    16.8 ± 0.4      16.6 ± 0.4     16.6 ± 0.4
  Weight before treatment (g)      31.5 ± 4.3    28.1 ± 3.8      26.8 ± 4.7     29.1 ± 3.1
  Weight end of treatment (g)      32.5 ± 4.6    28.3 ± 2.6      28.1 ± 4.4     29.3 ± 3.6
  Systolic blood pressure (bpm)    86.3 ± 24.8   117.4 ± 16.0    107.8 ± 36.4   108.2 ± 22.6
  Diastolic blood pressure (bpm)   61.8 ± 29.0   76.2 ± 11.9     75.1 ± 43.1    76.7 ± 24.7

Data is shown as mean ± standard deviation;

∗

at the end of the treatment period; weight and blood pressure analyzed by two-way ANOVA with Tukey's post hoc analysis; age analyzed by one-way ANOVA with Tukey's post hoc analysis, NTL, non-transgenic littermates.

Functional Magnetic Resonance Imaging
-------------------------------------

All MRI scans were performed on a 7/16 small animal MR Pharmascan (Bruker Biospin GmbH, Ettlingen, Germany) equipped with an actively shielded gradient set of 760 mT/m with a 80 μs rise time and operated by a Paravision 6.0 software platform (Bruker Biospin GmbH, Ettlingen, Germany). Mice were anesthetized with an initial dose of 4% isoflurane (Abbott, Cham, Switzerland) in oxygen/air (200/800 μl/min) mixture and anesthesia were maintained at 1.5% isoflurane in oxygen/air (100/400 μl/min) mixture. Mice were placed in prone position on a water-heated support to keep body temperature within 36.5 ± 0.5°C. Body temperature was monitored with a rectal temperature probe.

Perfusion MRI was performed using an arterial spin labeling technique as described previously ([@B37]). The Paxinos mouse brain atlas was used as anatomical reference for scan positioning and analysis ([@B43]). Re-assessment of CBF (test--retest analysis) was performed in 17 mice randomly selected from the groups for assuring the repeatability of the CBF measurement (*n* = 17).

Cerebral vascular reactivity was assessed, after a 1 week of recovery following perfusion MRI, by measuring cerebral blood volume (CBV) changes upon pharmacological stimulation using vessel dilator acetazolamide, as previously reported ([@B36]; [@B45]). The scanner was equipped with a 300 MHz cryogenic radiofrequency probe for conducting the CVR assay. Mice were endotracheally-intubated and maintained at 1.5% isoflurane in oxygen/air (100:400 μl/min) mixture and actively ventilated at a rate of 90 breaths/minute and a tidal volume of approximately 0.3 μl/breath using a small animal ventilator (MRI-1, CWE, Inc., United States). Animal's tail veins were cannulated for administration of drugs and contrast agent. A neuromuscular blocking agent gallanmine triethiode (Sigma-Aldrich GmbH, Switzerland) was administered twice as a bolus (40 μl, 7 mg/ml) at the beginning and before *i.v.* injection of contrast agent while the isoflurane level was reduced to 1.2%. T~2~-weighted anatomical reference images were acquired using a spin echo rapid acquisition with relaxation enhancement (RARE) sequence with the same anatomical geometry as RARE sequence at pre- and post-injection of vessel dilator acetazolamide. Fifteen minutes after injection of contrast agent, of gallanmine was injected *i.v.* (21 mg/kg body weight). Then, eight sequential pre-contrast agent scans at baseline signal intensity *S*~pre~ (CBV~0~ image) were acquired using a RARE sequence: temporal resolution = 40 s, repetition time = 3333 ms, echo time ~eff~ = 81 ms, RARE factor = 32, field-of-view = 20 mm × 20 mm, imaging matrix = 133 × 103, slice thickness = 1 mm, 1.5 mm gap, resolution = 150 μm × 200 μm. FLASH sequence NR = 50 was used for ensuring the successful injection of the contrast agent. After 10 repetitions, iron oxide contrast agent Endorem (50 mg Fe/kg body weight, Guerbet SA, Roissy-en-France, France) was administered *i.v.* A RARE sequence was started after 5 min after repetition = 100 and 8 averages, when the contrast agent concentration had reached steady state. After the 30^th^ repetition (20 min), acetazolamide (30 mg/kg body weight; Diamox^®^ parenteral, Goldshield Pharmaceuticals, Ltd., Croydon, United Kingdom) was administered *i.v.* as a bolus. Additional 70 images were collected (46.7 min), yielding the image series *S*~(~*~t~*~)~.

Brain Tissue Collection
-----------------------

After MRI, mice were anesthetized under ketamine/xylazine/acepromazine maleate (75/10/2 mg/kg body weight, bolus injection, *i.p.*). Mice were perfused using cold PBS (pH 7.4). Brains were removed from the skull. The left brain hemispheres were fixed in 4% paraformaldehyde (Sigma-Aldrich, Switzerland) in PBS (pH 7.4) at 4°C and embedded in paraffin following routine procedures. The right hemispheres were snap frozen and stored at -80°C, until use.

Meso Scale Discovery (MSD) Analysis
-----------------------------------

Meso Scale Discovery (MSD) analysis was performed as described previously ([@B26]) in NTL (*n* = 6), NTL noscapine (*n* = 8), arcAβ (*n* = 7), and arcAβ noscapine (*n* = 4) mice. In brief, frozen brain tissues were homogenized using a glass Teflon homogenizer with homogenization buffer containing 100 mM Tris-HCl, 150 mM NaCl and complete EDTA-free protease inhibitor cocktail (Roche Diagnostic, Risch-Rotkreuz, Switzerland). The amount of buffer used was equivalent to 10-fold wet weight of the brain tissue. The brain homogenates were centrifuged at 100,000 *g* for 1 h and supernatants were collected Tris-buffered saline (TBS) fraction and pellets were homogenized again in homogenization buffer containing 2% of sodium dodecyl sulfate (SDS). Centrifugation was repeated and the supernatants (SDS-fraction) were again collected. The remaining pellet was suspended in 70% formic acid (FA), sonicated four times for 30 s at 30% power and again centrifuge at 100,000 *g* for 30 min. The supernatants were collected (FA-fraction), lyophilized and reconstituted in homogenization buffer. Aβ~38~, Aβ~40~, and Aβ~42~ levels were measured in the abovementioned brain homogenate fractions using an MSD 3plex multi-SPOT Aβ human kit (Gaithersburg, MD, United States). Plates were measured on an MSD SECTOR Imager 600 plate reader (Gaithersburg, MD, United States). The MSD DISCOVERY WORKBENCH software (Version 3.0.18) (Gaithersburg, MD, United States) with Data Analysis Toolbox was used to calculate sample concentrations by comparing them against a standard curve.

Immunohistochemistry
--------------------

Cy3-6E10 (mouse anti-Aβ-SIG-39320, Signet Laboratories, United States, 1:5000 dilution) and Alexa488-ionized calcium-binding adapter molecule (Iba1, Rabbit anti-Iba1, Wako Chemicals, United States, HRP Rabbit AK, 1:2500 dilution) immunostainings were done on 5 μm brain sections as previously described ([@B48]). Nuclei were counterstained by DAPI, while adjacent sections were stained with hematoxylin and eosin. Images were examined using Leica DM 4000B microscopy with Olympus DP71 digital camera and VIS (Visiopharm Integrator System) version 4.4.6.9 software at 5×, 10×, 20×, and 40× magnification. Images were captured on each slices at (× 5, 10, 20, 40 magnification). Quantification of the images was performed blinded using Image J (NIH, United States). For quantitative image analysis, the cortex and hippocampus were analyzed on three equidistant sagittal hemibrain sections of each mouse (interaural lateral 0.60 to 0.72 mm) at 10×, three images taken at each region on one slice. Images of the cortex and hippocampus were taken with an exposure time of 200 ms (amyloid, 6E10-Cy3), 308 ms (microglia, Iba1-Alexa488), 30 ms (nucleus, DAPI) of the same areas. The Paxinos mouse brain atlas was used as anatomical reference ([@B43]). Threshold and particle analysis functions were applied, resulting in Aβ and microglia covered area in percentage.

Data Analysis
-------------

Two persons performed data analysis independently, and the obtained results were averaged. CBF maps from arterial spin labeling data was computed as previously described ([@B37]). Region of interest (ROIs) were evaluated in the cerebral cortex, hippocampus and thalamus using AFNI (NIH, United States) with T~2~-weighted anatomical scan and the Paxino mouse brain atlas as reference ([@B43]). [Figure 2A](#F2){ref-type="fig"} shows the placement of the ROIs on the anatomical scans, which were transferred to the CBF map. CBF in ROIs was calculated from both T~1~ values ([@B54]) using MATLAB R2015b (The Mathworks, Natick, MA, United States):
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where λ is the blood/tissue partition coefficient for water, assumed to be 0.9 μl/g ([@B29]) and T~1~ blood was assumed to be 2.007 s at 7 T ([@B55]).

Assessment of CVR was performed using Biomap 6 (Novartis Institute for Biomedical Research, Basel, Switzerland). The ROIs were defined in six brain regions (motor cortex, sensory cortex, striatum, hippocampus, thalamus, and cerebellum). Baseline CBV (CBV~0~) was calculated for each ROI. The baseline CBV and relative percentage changes of CBV versus baseline CBV (ΔCBV(*t*)) were computed on a pixel-by-pixel basis according to:
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Linear regression analysis was performed on the square root of the Δ*CBV% (t)*, sqrt(Δ CBV% (t)) with time. ROIs of specific brain regions in the left and right hemispheres were merged into one ROI. [Figure 3A](#F3){ref-type="fig"} shows the placement of the ROIs for analyzing the CBV data using T~2~-weighted anatomical scan and the Paxino mouse brain atlas as reference ([@B43]). The response time curve ΔCBV (*t*) and the late ΔCBV(%) of slices 90--100 (40--46.7 min) were compared between groups.

Statistical Analysis
--------------------

For comparison of the continuous numeric data such as weight, blood pressure before and after treatment, a two-way ANOVA with Tukey's *post hoc* analysis (GraphPad Prism 6.0, San Diego, CA, United States) was used. For comparison of age between groups, a one-way ANOVA with Tukey's *post hoc* analysis was used. For comparison of bradykinin plasma level between NTLs and arcAβ mice, unpaired *t*-test was used after Shapiro--Wilk normality test. For group comparison of CBF, CBV~0~, late ΔCBV(%), slope of sqrt(ΔCBV%(t)) and immunostaining of Aβ and Iba1 in multiple brain regions, two-way ANOVA with Turkey's *post hoc* analysis were used. For MSD measurement of Aβ level in different brain fractions of test--retest analysis of the CBF data of the same mice, a Pearson correlation analysis was performed. All data are present as mean ± standard deviation. Significance was set at ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001.

Results
=======

Demographics and Blood Pressure
-------------------------------

Demographic information, body weight before/after the treatment and blood pressure are summarized in [Table 1](#T1){ref-type="table"} including NTL (*n* = 8), NTL noscapine (*n* = 9), arcAβ (*n* = 9), and arcAβ noscapine (*n* = 11). One-way ANOVA showed that groups did not differ in terms of age among the groups (approximately 16.6 months-old after the treatment), F(DFn, DFd): *F*(3,33) = 0.4467, *p* = 0.7212. And no differences between body weights before and after the treatment period were found between groups *F*(3,66) = 0.104, *p* = 0.9574. As inhibitors of BRs can affect the angiotensin system ([@B1]; [@B17]), we measured the systolic and diastolic blood pressure in mice at the end of the treatment period. Blood pressure was not statistically different between noscapine-treated NTLs, and arcAβ mice compared to untreated groups *F*(3,33) = 0.1594, *p* = 0.9229 ([Table 1](#T1){ref-type="table"}).

Increased Plasma Levels of Bradykinin 1--5 in arcAβ Mice
--------------------------------------------------------

We tested with enzyme immunoassay if kallikrein-kinin system is activated in the arcAβ mouse model of amyloidosis. We detected that arcAβ mice have higher levels of circulating bradykinin in the plasma, as compared to NTLs (33.2 ± 10.5 vs. 20.3 ± 7.43 ng/ml, *p* = 0.0338, Shapiro--Wilk *p* = 0.2514 and *p* = 0.3587 respectively, passing normality test) ([Figure 1](#F1){ref-type="fig"}).

![Bradykinin levels in the plasma of arcAβ mice and non-transgenic littermates (NTLs) measured by using enzyme immunoassay. ArcAβ mice (*n* = 6) have higher levels of circulating bradykinin, as compared to NTL (*n* = 6); ^∗^*p* \< 0.05, unpaired Student's *t*-test; Shapiro--Wilk *p* = 0.2514 and *p* = 0.3587, respectively passing normality test.](fnagi-11-00027-g001){#F1}

Noscapine Treatment Ameliorated Regional Hypoperfusion
------------------------------------------------------

We first tested the effect of chronic oral noscapine treatment on cerebral perfusion of arcAβ mice. [Figure 2A](#F2){ref-type="fig"} shows the placement of acquisition slice and ROIs of CBF analysis on the structural MRI image. [Figure 2B](#F2){ref-type="fig"} shows representative coronal CBF maps for all four groups of mice. Regional analysis of the perfusion MRI data showed the interaction between brain region and treatment × genotype with F(DFn,DFd): *F*(6,186) = 2.316, *p* = 0.0351; reduced CBF in the cortex (123.0 ± 40.8 vs. 165.4 ± 31.1 μl/100 g/min, *p* = 0.0192) and thalamus (154.1 ± 61.1 vs. 200.5 ± 38.4 μl/100 g/min, *p* = 0.0065) in untreated arcAβ mice compared to untreated NTLs were observed ([Figure 2C](#F2){ref-type="fig"}). Noscapine-treated arcAβ mice showed significantly higher CBF values in the cortex (167.6 ± 33.9 vs. 123.0 ± 40.8 μl/100 g/min, *p* = 0.0023) and thalamus (196.3 ± 43.8 vs. 154.1 ± 61.1 μl/100 g/min, *p* = 0.0043) compared to untreated arcAβ mice. The test--retest results of two perfusion MRI measurements in the same mice are shown in [Supplementary Figure 2](#SM1){ref-type="supplementary-material"}. Pearson correlation analysis showed a robust correlation (*r* = 0.9491, *p* \< 0.0001, *n* = 17) between test and re-test measures. Taken together, perfusion imaging revealed that noscapine treatment mitigated the hypoperfusion seen in arcAβ mice of this age.

![Bradykinin receptor blockade by noscapine alleviates regional hypoperfusion in arcAβ mice. **(A)** Anatomical position of slice for arterial spin labeling on sagittal T~2~-weighted image (top) and representative regions of interest (ROI) \[cortex (red), hippocampus (yellow), and thalamus (blue)\] on coronal T~2~-weighted anatomical image acquired at the same position (bottom). **(B)** Representative coronal CBF maps (approximately Bregma --1.5 ± 0.3 mm) of untreated and noscapine-NTLs and arcAβ mice, respectively. **(C)** Quantification of regional CBF showed hypoperfusion in the cortex and thalamus of arcAβ compared with NTLs that is mitigated by noscapine treatment. Data are present as mean ± standard deviation; ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, two-way ANOVA with *post hoc* Turkey's correction for multiple comparison; CBF, cerebral blood flow. NTL (*n* = 8), NTL noscapine (*n* = 9), arcAβ (*n* = 9), arcAβ noscapine (*n* = 11).](fnagi-11-00027-g002){#F2}

Noscapine Treatment Mitigated Impaired CVR
------------------------------------------

We then tested the effect of noscapine treatment on the CVR by measuring CBV after stimulation with vessel dilator acetazolamide. One mouse in the un-treated NTLs, noscapine-treated NTLs and noscapine-treated arcAβ group showed negative ΔCBV and were categorized as outliers and thus excluded from further analysis. [Figure 3A](#F3){ref-type="fig"} illustrated the ROIs drawing on four different levels of MR slices identified using the Paxinos mouse brain atlas for CBV analysis ([@B43]). [Figure 3B](#F3){ref-type="fig"} illustrated the representative ΔCBV of different anatomical levels of mice at 46 min after-the injection of acetazolamide (*t* = 0 min) overlaid with corresponding T~2~-weighted MRI. No difference was observed in baseline CBV~0~ values among groups \[two-way ANOVA with Tukey's *post hoc* analysis, *F*(15,186) = 0.1919, [Supplementary Figure 3](#SM1){ref-type="supplementary-material"}\].

![Bradykinin receptor blockade ameliorates the reduced regional cerebral vascular reactivity in noscapine-treated arcAβ mice. **(A)** Representative ROI on coronal anatomical T~2~-weighted MR images at showing the motor cortex, sensory cortex, hippocampus, thalamus, striatum, and cerebellum. **(B)** Representative maps of percentage change in cerebral blood volume (ΔCBV) of untreated and noscapine-treated NTLs and arcAβ mice. Data are present as mean ± standard deviation; ΔCBV: percentage change in CBV.](fnagi-11-00027-g003){#F3}

In [Figure 4](#F4){ref-type="fig"} the change in ΔCBV is plotted as a function of time for the four groups of mice (*t* = -20 min: contrast agent injection; *t* = 0 min: acetazolamide stimulus). Linear regression analysis were performed on sqrt (%ΔCBV) with time (0--46.7 min). Two way ANOVA with Tukey's *post hoc* analysis showed significant interaction *F*(15,222) = 11.92, *p* \< 0.0001. The slope and intercept and goodness of the fitting are summarized in [Table 2](#T2){ref-type="table"}. A flatter slope of sqrt(%ΔCBV(t)) was observed in the motor cortex (*p* \< 0.001), sensory cortex (*p* \< 0.001) of untreated arcAβ compared to untreated NTLs. A significantly steeper slope was observed for noscapine-treated arcAβ compared to untreated arcAβ mice in the motor cortex (*p* = 0.0096), sensory cortex (*p* \< 0.0001), and thalamus (*p* = 0.0161).

![Regional cerebral vascular reactivity in mouse brain. **(A--F)** Percent change in cerebral blood volume (ΔCBV) plotted as a function of time for six brain regions (motor cortex, sensory cortex, hippocampus, striatum, thalamus, and cerebellum) of untreated and noscapine-treated NTLs and arcAβ mice, respectively. Injection of acetazolamide at *t* = 0 minute. Data are present as mean ± standard deviation; ^∗∗∗^*p* \< 0.001 NTL vs. arcAβ, ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, and ^\#\#\#^*p* \< 0.001 arcAβ vs. arcAβ-noscapine, two-way ANOVA with *post hoc* Tukey's correction for multiple comparison. NTL (*n* = 8), NTL noscapine (*n* = 9), arcAβ (*n* = 9), and arcAβ noscapine (*n* = 11).](fnagi-11-00027-g004){#F4}

###### 

Linear regression analysis of square root (ΔCBV%) along with time in mice.

  Region            NTL         NTL noscapine   arcAβ           arcAβ noscapine      
  ----------------- ----------- --------------- --------------- -------------------- -----------------------
  Motor cortex      Slope       0.061 ± 0.002   0.066 ± 0.002   0.048 ± 0.001^∗∗∗^   0.057 ± 0.001^\#\#^
                    Intercept   2.178 ± 0.056   1.747 ± 0.047   1.4 ± 0.023          2.379 ± 0.037
                    *R*         0.9243          0.9523          0.9773               0.9614
  Sensory cortex    Slope       0.064 ± 0.003   0.069 ± 0.004   0.038 ± 0.002^∗∗∗^   0.054 ± 0.003^\#\#\#^
                    Intercept   3.120 ± 0.087   3.383 ± 0.096   3.164 ± 0.058        2.989 ± 0.082
                    *R*         0.8462          0.8399          0.8172               0.8162
  Hippocampus       Slope       0.045 ± 0.002   0.047 ± 0.002   0.050 ± 0.002        0.050 ± 0.002
                    Intercept   2.451 ± 0.047   2.127 ± 0.055   2.503 ± 0.048        2.959 ± 0.066
                    *R*         0.9036          0.8816          0.917                0.8556
  Thalamus          Slope       0.042 ± 0.002   0.078 ± 0.003   0.049 ± 0.002        0.058 ± 0.002^\#^
                    Intercept   2.549 ± 0.063   2.669 ± 0.090   2.690 ± 0.044        2.731 ± 0.062
                    *R*         0.8179          0.8829          0.9258               0.8999
  Caudate nucleus   Slope       0.054 ± 0.001   0.065 ± 0.001   0.059 ± 0.002        0.053 ± 0.002
                    Intercept   1.826 ± 0.032   1.327 ± 0.034   1.376 ± 0.043        1.848 ± 0.045
                    *R*         0.9666          0.9744          0.9515               0.9334
  Cerebellum        Slope       0.035 ± 0.003   0.045 ± 0.003   0.035 ± 0.001        0.037 ± 0.002
                    Intercept   3.342 ± 0.075   2.946 ± 0.075   2.619 ± 0.033        2.429 ± 0.050
                    *R*         0.6884          0.7877          0.9198               0.8486

Data is shown as mean ± standard error of the mean;

∗∗∗

p \< 0.001 NTL vs. arcAβ,

\#

p \< 0.05,

\#\#

p \< 0.01, and

\#\#\#

p \< 0.001 arcAβ vs. arcA β-noscapine, two-way ANOVA with Tukey's post hoc analysis; NTL (n = 8), NTL noscapine (n = 9), arcAβ (n = 9), arcAβ noscapine (n = 11).

Two-way ANOVA with Tukey's *post hoc* analysis showed the interaction between brain region and treatment × genotype with *F*(15,2244) = 8.3167, *p* \< 0.0001; significantly reduced late ΔCBV (average of *t* = 40--46.7 min) was observed in untreated arcAβ mice compared to untreated NTLs in the motor cortex (12.5 ± 8.3 vs. 28.9 ± 26.1%, *p* \< 0.0001), sensory cortex (24.0 ± 15.1 vs. 30.4 ± 11.8%, *p* = 0.0219) ([Supplementary Figure 4](#SM1){ref-type="supplementary-material"}). Higher late ΔCBV was observed in noscapine-treated arcAβ compared to untreated arcAβ mice in the motor cortex (24.6 ± 19.9 vs. 12.5 ± 8.3%, *p* \< 0.0001) and hippocampus (26.9 ± 17.9 vs. 21.1 ± 10.0%, *p* = 0.0174). Taken together, measurements of CBV upon acetazolamide stimulation showed that noscapine treatment rescued the reduced CVR in cortical and subcortical regions of arcAβ mice.

Noscapine Did Not Affect Microglia Activation and Beta-Amyloid Level
--------------------------------------------------------------------

Previous reports about the effect of B~1~R and B~2~R blockade on neuroinflammation and Aβ load in animal models of AD have been contradictory. We therefore analyzed microgliosis and Aβ load in all groups of mice by immunohistochemistry ([Figure 5](#F5){ref-type="fig"}). Two-way ANOVA analysis indicated that noscapine treatment had no influence on amyloid burden in the arcAβ mice as revealed by quantitative analysis of 6E10 immunostainings in the cortex (% 6E10 area, 1.37 ± 0.42 vs. 0.97 ± 0.44, ns) or in the hippocampus (1.44 ± 0.83 vs. 1.09 ± 0.59, ns), Tukey's *post hoc* analysis *F*(1,16) = 0.004815, *p* = 0.9455). Moreover, microgliosis Iba1 immunoreactivity was significantly higher in the cortex (0.50 ± 0.32 vs. 0.19 ± 0.09, *p* = 0.0279) of untreated arcAβ mice compared to NTLs, but not in the hippocampus. The microgliosis Iba1 immunoreactivity was similar between noscapine-treated and untreated NTLs in the cortex (0.18 ± 0.07 vs. 0.19 ± 0.09, ns), and the hippocampus (0.10 ± 0.07 vs. 0.21 ± 0.14, ns); and between noscapine-treated and untreated arcAβ mice in the cortex (0.53 ± 0.07 vs. 0.50 ± 0.32, ns) and the hippocampus (0.28 ± 0.04 vs. 0.21 ± 0.14, ns) \[two-way ANOVA with Tukey's *post hoc* analysis *F*(3,34) = 1.399, *p* = 0.2599\]. These results suggest that B~1~R and B~2~R blockade with noscapine at this dosage and duration did not alter the amyloid load and degree of Aβ-associated microgliosis.

![Immunohistochemical analysis of Aβ load and microglia activation. **(A)** Brain tissue sections of untreated and noscapine-treated NTLs and arcAβ mice were stained for amyloid (6E10, red), microglia (Iba1, green) immunoreactivity in the cortex (ctx) and hippocampus (hippo) of untreated and noscapine-treated NTLs and arcAβ mice, respectively. Scale bar = 400 μm. **(B)** Quantification of immunoreactivity. Data are present as mean ± standard deviation; Iba1: ionized calcium-binding adapter molecule 1. ^∗^*p* \< 0.05, two-way ANOVA with Tukey's *post hoc* correction for multiple comparison. NTL (*n* = 5), NTL noscapine (*n* = 5), arcAβ (*n* = 5), and arcAβ noscapine (*n* = 5).](fnagi-11-00027-g005){#F5}

### MSD Analysis

We used MSD immunoassay to determine Aβ levels in three protein fractions from the brain hemispheres. Two-way ANOVA with Tukey's *post hoc* analysis showed greater amount of Aβ~38~ (10747.1 ± 2977.4 vs. 164.8 ± 57.8, *p* \< 0.0001), Aβ~40~ (27222.3 ± 6376.1 vs. 35.5 ± 9.0, *p* \< 0.0001), and Aβ~42~ (2679.3 ± 737.7 vs. 14.3 ± 4.7, *p* \< 0.0001) in FA fractions brain homogenates ([Figure 6](#F6){ref-type="fig"}) from arcAβ mice (*n* = 7) compared to NTLs (*n* = 6). No significant difference was detected in the level of Aβ~38~, Aβ~40~ and Aβ~42~ in TBS, SDS, and FA fractions between noscapine-treated arcAβ mice (*n* = 4) and untreated arcAβ mice (*n* = 7).

![Meso Scale Discovery (MSD) analysis of Aβ load in TBS, SDS and FA fraction of mouse brain homogenates from untreated and noscapine-treated NTLs and arcAβ mice **(A)** Aβ~38~; **(B)** Aβ~40~; **(C)** Aβ~42~. ^∗∗∗^*p* \< 0.001, two-way ANOVA with Tukey's *post hoc* correction for multiple comparison. NTL (*n* = 6), NTL noscapine (*n* = 8), arcAβ (*n* = 7), and arcAβ noscapine (*n* = 4) mice.](fnagi-11-00027-g006){#F6}

Discussion
==========

In the current study, we showed using fMRI techniques a pronounced vascular dysfunction in the arcAβ mouse model of cerebral amyloidosis. Chronic administration of B~1~R and B~2~R antagonist noscapine ameliorated amyloidosis-associated cerebral hypoperfusion and vascular reactivity, but did not affect Aβ cerebral load and associated microgliosis.

Activation of the Kallikrein-Kinin System in a Transgenic Mouse Model of Cerebral Amyloidosis
---------------------------------------------------------------------------------------------

The kallikrein-kinin system has been shown to be activated both in patients with AD and in animal disease models ([@B5]; [@B51]; [@B27]). In the central nervous system, BRs are mainly distributed in the cortex and hippocampus, the brain structures that are affected earliest by AD pathologies ([@B18]; [@B2]). In the brain B~1~R and B~2~R are expressed in a variety of cells including neurons, astrocytes, microglia, oligodendrocytes, and endothelial cells. Upregulation of brain BR levels was shown in rats ([@B52]), mice ([@B44]) in response to infusion of human Aβ, as well as in transgenic mouse models of cerebral amyloidosis ([@B27]; [@B42]). Also, increased B~2~R density was demonstrated by ^3^H-bradykinin binding assay in skin fibroblasts from patients with AD compared to that from age-matched healthy controls ([@B40]). In the present study, we showed that arcAβ mice of amyloidosis have increased plasma bradykinin levels as compared to NTLs at the endpoint of the study. The arcAβ mouse model of cerebral amyloidosis exhibits cerebral plaque deposition from 6 months-of-age together with strong congophilic cerebral amyloid angiopathy ([@B25]) and increased bradykinin plasma levels may likely be due to vascular amyloid deposition.

BRs as Pharmacological Targets in AD
------------------------------------

Previous studies using animal models of AD have described BRs blockade as a potential treatment strategy for AD. Pharmacological blockade of both BRs in transgenic mice over-expressing amyloid precursor protein or mice infused with Aβ has been shown to improve learning and memory formation. B~1~R blockade mitigated cognitive deficits by B~1~R antagonist des-Arg9\[Leu8\]-bradykinin in Aβ-treated mice ([@B44]) and in rat ([@B7]), and by B~1~R antagonist SSR240612 in Tg-SwDI mice of AD ([@B27]). B~2~R blockade by HOE 140 protected against cognitive impartment in Aβ-infused mice ([@B44]; [@B6]).

It has been described that B~2~Rs are constitutively expressed and mediate most physiological actions of kinins, whereas B~1~Rs are highly inducible upon inflammatory stimulation and tissue injury ([@B33]). Thus, the majority of previous preclinical studies have focused on B~1~R inhibition. However, it has been described that the expression of both receptors is increased under pathological conditions related to oxidative stress, pro-inflammatory stimuli (e.g., inflammation and infection) as well as vasoactive peptides of the renin-angiotensin system ([@B41]). Thus, we have used noscapine a phthalideisoquinoline alkaloid, which is an antagonist for both B~1~R and B~2~R (pA2 = 6.68) ([@B31]). We decided to provide the drug in drinking water as an easy administrable way for chronic pharmacological treatment, but which might have introduced variability in the treatment effect due to different uptake of the drug by the mice. Noscapine has been clinically approved as antitussive drug, and has the advantage that it can be administered orally, that its pharmacokinetics and metabolic fate are characterized, and that it has low toxicity ([@B13]; [@B50]; [@B20]).

Blockade of B~1~R and B~2~R Ameliorates Cerebrovascular Dysfunction
-------------------------------------------------------------------

We used established functional MRI protocols to assess the effects of noscapine treatment on cerebrovascular dysfunction *in vivo* ([@B24]; [@B37]). Cerebrovascular dysfunction is an early pathological event in patients with AD ([@B16]). The brain critically depends on the continuous supply of oxygen and nutrients for proper cognitive function, and thus CBF is a tightly regulated process. In a previous study it was shown with Laser Doppler flowmetry in the J20 mouse model that blockade of B~1~R improves CBF ([@B27]). We have assessed CBF using a non-invasive arterial spin labeling technique. We showed a 25% reduction in CBF in the cortex of approximately 17-months-old arcAβ mice compared to age-matched NTLs. In a previous study using the same fMRI technique we found normal CBV values in 6-months-old arcAβ mice and a 30% reduction in CBF in the cortex of 24-months-old arcAβ mice compared to NTLs ([@B38]), which indicates that the severity of the CBF reduction increased with increasing age in that mouse model. With perfusion MRI, we observed that noscapine treatment reversed the pathological hypoperfusion in the cortex and thalamus in arcAβ mice.

Cerebral vascular reactivity reflects the capacity of blood vessels to dilate and is an important indicator of the brain vascular reserve capacity. Dynamic measurement of CBV upon acetazolamide challenge is commonly used in humans and animals for quantification of CVR and has shown to be impaired in AD patients and models of cerebral amyloidosis ([@B49]; [@B36]; [@B45]; [@B12]). Acetazolamide inhibits carbonic anhydrase, which results into increased CBV, but its exact mode of action is not yet clear ([@B53]; [@B12]). In our study we observed a global reduction in CVR in the cortical and subcortical regions in untreated arcAβ mice compared to NTLs. A previous fMRI study has described a reduction of CVR in cortical regions but not subcortical regions in 16-months-old arcAβ mice that was aggravated with aging ([@B45]). These differences in CVR in subcortical regions of arcAβ mice might be due to the fact that mice although being of the same strain were from different colonies. Biological factors such as genetic backgrounds (our arcAβ mice were derived from transgenic mouse strain back-crossed to C57BL6 for over 10 generations compared to mice in the previous study which had been on a mixed genetic background) and environmental factors such as housing conditions can affect the phenotype. In the current study we found that treatment with noscapine ameliorated CVR reduction in arcAβ mice, which is in line with a previous study that blockade of B~1~R significantly ameliorated sensory-evoked hemodynamic responses in the J20 mouse model ([@B27]). As inhibition of BRs can affect the angiotensin system ([@B1]; [@B17]), we measured systolic and diastolic blood pressure between groups. As we did not observe differences in blood pressure values among groups, we ruled out that the observed ΔCBV differences were due to actions of noscapine on the angiotensin system.

The findings from CVR and CBF measurement clearly demonstrate that inhibition of B~1~R and B~2~R ameliorate Aβ-induced cerebrovascular dysfunction. The molecular mechanisms underlying cerebrovascular dysfunction in AD are not well-understood and it can only be speculated how noscapine treatment ameliorated hypoperfusion and reduced CVR in arcAβ mice. It has been suggested that blockade of BRs antagonized the production of vascular reactive oxygen species and inflammatory cytokines ([@B27]; [@B41]), which might have contributed to the restoration of the vascular reactivity ([@B22]).

Blockade of B~1~R and B~2~R Does Not Alter Neuropathology
---------------------------------------------------------

In addition to functional vascular effects of noscapine treatment, we also assessed the effects on neuroinflammation and Aβ pathology. Gliosis is an early phenomenon both in mouse models of amyloidosis ([@B46]; [@B30]) and in patients with AD ([@B15]). Activated microglia surrounding amyloid deposits and upregulated pro-inflammatory cytokines have been reported in the arcAβ mice ([@B25]; [@B22]) and we have seen also microglia activation in the brains of noscapine-treated and untreated arcAβ mice.

B~1~R is involved in inflammation in the central nervous system mainly through the activation of microglia ([@B3]) and astrocytes ([@B27]). However, the effects of bradykinin inhibition on microglia and astrocytes have been inconsistent, both suppression ([@B7]) and stimulation ([@B4]) of neuroinflammation has been reported, or showed no effect ([@B4]). Using measurements of Iba1 immunoreactivity in few selected animals from each group, we found no effect of chronic oral noscapine treatment on microglia activation. In the current study, we have used Iba1 immunoreactivity as a rough estimate of neuroinflammation and have not attempted to discriminate the different types of microglia (resting and activated), which would require a more elaborate histological analysis. In addition, other markers of neuroinflammation (for example GFAP, CD68, etc.) and larger groups of animals might be investigated.

Reports on the effect of B~1~R and B~2~R on Aβ load have also been contradictory. B~2~R activation promoted α-secretase processing of amyloid precursor protein in skin fibroblasts from patients with AD, resulting in a lower production of Aβ ([@B39]). B~1~R antagonist SSR240612 reduced Aβ deposition ([@B27]) in Tg-SwDI mouse model of AD amyloidosis, while another B~1~R antagonist R-715 treatment increased Aβ~40~ and fibrillar Aβ deposition in both transgenic mouse models of AD, Tg-SwDI ([@B42]) and 5 × familial mice ([@B4]). Aβ can in turn activate the release of kinins in cultured endothelial cells ([@B19]). In our study, using immunohistochemical analysis of brain section and MSD immunoassay of brain tissue we found no effect of inhibition of B~1~R and B~2~R inhibition on cerebral Aβ load.

Methodological Considerations
-----------------------------

The reported differences in the action of bradykinin receptor inhibitors might be due to the affinity of individual inhibitors to B~1~R and B~2~R, as well as other factors like pharmacokinetics, biodistribution of the drug used, and the timing, dose and duration of the treatment. In our study, we found amelioration of cerebrovascular dysfunction with chronic oral noscapine treatment, while the treatment seemed to have no effects on cerebral Aβ load and microglia activation. In that context, fMRI could constitute a more sensitive and earlier indicator of treatment response than histological or biochemical assessment. It might be, however, conceivable that a different dose of noscapine or longer treatment periods might have also led to detectable changes in neuropathology. In addition, we started treatment in arcAβ mice at an advanced disease stage, which limited the potential effect scale on the different read-outs. Importantly, we have not used behavioral read-outs to assess effects of noscapine treatment on the cognitive deficit in arcAβ mice ([@B25]) and thus do not know if noscapine has led to an improvement of cognitive function. Thus, more extensive studies using additional behavioral read-outs, and starting treatment at an early disease stage are needed to demonstrate the full potential of noscapine treatment on AD pathology.

Conclusion
==========

Long-term oral noscapine treatment alleviates brain hypoperfusion and restores CVR in an animal model of amyloidosis as revealed by fMRI. Blocking BRs represents a potential target for treatment of AD-associated cerebrovascular dysfunction.
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